{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T04:59:26Z","timestamp":1755925166051,"version":"3.40.4"},"reference-count":15,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2002]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. &lt;i&gt;Methods:&lt;\/i&gt; A total of 73 patients with PS (ECOG) 0\u20132, aged &lt;70 years and adequate bone marrow, renal, liver and cardiac functions were included in the study (13 stage III B and 60 stage IV). The schedule of administration was doxorubicin 50 mg\/m&lt;sup&gt;2&lt;\/sup&gt; by intravenous (i.v.) 30\u00a0min injection on day 1 followed the day after by docetaxel 75 mg\/m&lt;sup&gt;2&lt;\/sup&gt;, by i.v. 60 min infusion. Cycles were repeated every 28 days. &lt;i&gt;Results:&lt;\/i&gt; Overall, the median number of administered cycles was 6 (range 1\u201314). The most common toxicity was hematological, with 56.2% of the patients who experienced grade 3\u20134 neutropenia. However, febrile neutropenia occurred only in 2.8% of the cases. The median cumulative dose of doxorubicin was 350 mg\/m&lt;sup&gt;2&lt;\/sup&gt; (range 50\u2013700 mg\/m&lt;sup&gt;2&lt;\/sup&gt;). Eleven patients (15.4%) were documented to have &gt;10% but &lt;20% decrease in the left ventricular ejection fraction. No case of congestive heart failure was recorded. No patient experienced treatment-related death. Among the 68 evaluable patients, the overall objective response rate was 73.5% (95% confidence limits: 63\u201384%): 10 patients (14.7%) obtained a complete remission and 40 (58.8%) had a partial response. Only 10 patients (14.7%) experienced progressive disease. The median duration of response was 10 months (2\u201354+). &lt;i&gt;Conclusion:&lt;\/i&gt; This sequential treatment with doxorubicin and docetaxel is an effective, feasible and a well-tolerated regimen. The main toxicity was neutropenia. The lack of cardiotoxicity is an important advantage of such a doxorubicin-docetaxel combination and it justifies phase III comparative studies with other anthracyclines\/taxanes containing schedules in both advanced and early-stage breast cancer.<\/jats:p>","DOI":"10.1159\/000065466","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:17Z","timestamp":1050440717000},"page":"205-212","source":"Crossref","is-referenced-by-count":9,"title":["Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer"],"prefix":"10.1159","volume":"63","author":[{"given":"S.","family":"Palmeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tamburo De Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vaglica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Accurso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Failla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Agostara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Massidda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2002,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199504133321507"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F83.4.288"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1021%2Fbi00062a003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007%2FBF00686042"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2FBF00666492"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1026418831238"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F86.2.143"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0959-8049%2899%2900122-7"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1026437731354"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1026441804889"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008392927656"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008351310818"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097%2F00000421-200104000-00008"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1006194909859"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1054%2Fbjoc.2000.1306"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:30:39Z","timestamp":1745469039000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000065466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000065466","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2002]]}}}